Lars Christian Stugaard has been appointed as acting CEO of DiaGenic on an interim basis effective from April 1 2014. Stugaard holds the position as CEO in Strata Marine & Offshore and has worked in the Ferncliff group since 2003. During his 11-year tenure with Ferncliff, he has been working with financial management, general business development and analysis.
DiaGenic is a Norwegian diagnostic company that develops in vitro diagnostic (IVD) products for early detection of diseases. DiaGenic claims to be a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer's disease.